Doxorubicin

Single agent: 60 to 75 mg/m 2 given intravenously every 21 days, In combination: 40 to 75 mg/m 2 given intravenously every 21 to 28 days, Discontinue Doxorubicin Hydrochloride Injection in patients who develop signs or symptoms of cardiomyopathy, Reduce dose in patients with hepatic impairment 2.1 Recommended Dosage for Adjuvant Breast Cancer The recommended dosage of Doxorubicin Hydrochloride Injection is 60 mg/m 2 administered as an intravenous bolus on day 1 of each 21-day treatment cycle, in combination with cyclophosphamide, for a total of four cycles.

Directions from the U.S. FDA-approved label — your doctor or pharmacist may advise differently.

Doxorubicin Hydrochloride Injection are contraindicated in patients with: Severe myocardial insufficiency, Recent (occurring within the past 4–6 weeks) myocardial infarction, Severe persistent drug-induced myelosuppression, Severe hepatic impairment (defined as Child Pugh Class C or serum bilirubin level greater than 5 mg/dL), Severe hypersensitivity reaction to doxorubicin hydrochloride, including anaphylaxis, Severe myocardial insufficiency, Recent myocardial infarction, Severe persistent drug-induced myelosuppression, Severe hepatic impairment, Severe hypersensitivity to doxorubicin hydrochloride

Excerpt from the U.S. FDA-approved label. Talk to a pharmacist or doctor before use.

Radiation-Induced Toxicity: Can be increased by the administration of Doxorubicin Hydrochloride Injection. Radiation recall can occur in patients who receive Doxorubicin Hydrochloride Injection after prior radiation therapy., Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential of the potential risk to a fetus and on the use of effective contraception. Advise males with female partners of reproductive potential to use effective contraception. Advise males with pregnant partners to use condoms.

Warnings and precautions excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor before use.

The following clinically significant adverse reactions are described elsewhere in the labeling., Cardiomyopathy and Arrhythmias, Secondary Malignancies, Extravasation and Tissue Necrosis, Severe Myelosuppression, Tumor Lysis Syndrome, Radiation Sensitization and Radiation Recall The most common (>10%) adverse reactions are alopecia, nausea and vomiting. To report SUSPECTED ADVERSE REACTIONS, contact Pfizer, Inc.

Excerpt from the U.S. FDA-approved label — not a complete list. Talk to a pharmacist or doctor about side effects.

97 products from 43 makers in the NepalDoc medicine catalog use this generic:

Showing 30 of 97 catalog products. Search the full catalog in the app.

Brand list from the NepalDoc medicine catalog. Availability varies by pharmacy — call ahead to confirm stock.

Store all vials at 2°C to 8°C (36°F to 46°F). Protect from light. Storage of Doxorubicin Hydrochloride Injection under refrigerated conditions can result in the formation of a gelled product. Place gelled product at room temperature for 2 to 4 hours to return the product to a slightly viscous, mobile solution.

Storage information from the U.S. FDA-approved label.